[Marrowforums]

We suggest posting links to articles like this one, rather than pasting the text into a post, since the original abstract will be better-formatted and easier to read:

Here is the link:

The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA)